For HER2+ early-stage breast cancer, Kadcyla is given as an intravenous (IV) injection every 3 weeks for a total of 14 cycles. For HER2+ metastatic breast cancer that has spread, Kadcyla is given once every 3 weeks on an ongoing basis. In both cases, you may need to stop treatment if the cancer returns or the side effects are intolerable.